Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

Slides:



Advertisements
Similar presentations
© 2015 Evidera. All Rights Reserved. Karin Hawkinson, Scientific Director, Global Market Access Communications Message communication vs. data dumping How.
Advertisements

Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
내과 R2 이지훈 N Engl J Med Sep 8.
Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
GOLD 2017 major revision: Summary of key changes
New inhalers for COPD and asthma 2015
Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Thank you for viewing this presentation.
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE):
Upfront Combination Therapy vs Step-Up Approach for PAH:
COPD Management.
Volume 149, Issue 5, Pages (May 2016)
Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.
Practical Recommendations for COPD:
Assessing COPD in Primary Care
COPD.
COPD by the Guidelines.
COPD Management.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.
Treatment Strategies in Mild to Moderate COPD
The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD
Improving Inhaler Technique
Making Decisions With Your Osteoarthritis Patients
Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.
Modern Strategies for Basal Insulin Use in T2D
COPD Management.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
New Perspectives in AF and PCI: Implications for the Practicing Physician.
What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?
Volume 153, Issue 4, Pages (April 2018)
Volume 153, Issue 4, Pages (April 2018)
Cost Effectiveness and Optimal Outcomes in HF
Understanding Statin Metabolism
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
When Would You Use Single Inhaler Triple Therapy in COPD?
Combination Inhaled Therapy in COPD: The Impact of Recent Data
Blood eosinophils as a marker of eosinophilic exacerbations in COPD
Cardiovascular Comorbidities A Common Occurrence With COPD
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
A Primer on Medication Delivery Systems in COPD Management
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
A Primer on Medication Delivery Systems in COPD Management
Understanding and Addressing the Needs of Patients With AD
Long-Acting Agents in Severe COPD
Are We Making Progress in the Management of Huntington Disease?
Personalizing COPD Therapy According to Recent Clinical Trial Evidence
Oral Prostacyclin Pathway Agents in PAH
Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.
Challenges in LA SCCHN.
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
A Multidisciplinary Perspective on the Management of Hypoparathyroidism.
Management of Chronic Stable COPD
Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.
The Nurse View: Spotlight on EGFR-Mutated NSCLC
Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Merging the Art and Science of Managing nOH in Clinical Practice
Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.
Practical Recommendations for COPD:
Targeted Care for COPD.
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.
PCSK9 Inhibitors and Real-World Evidence
Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.
Agenda. Diagnosis, Assessment, and Treatment of the COPD Patient in Primary Care.
Choosing inhaler therapy for patients with stable COPD based on the Global Initiative for Chronic Obstructive Lung Disease grouping. Choosing inhaler therapy.
What's New in NOACs in AF?.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice

Introduction

GOLD Recommendations: First-Line Pharmacologic Therapy for Stable COPD

Available and Emerging LABA and LAMA Bronchodilators for COPD

LABA/LAMA Dual Bronchodilation vs Monocomponents: Indacaterol/glycopyrronium

LABA/LAMA Dual Bronchodilation vs Monocomponents: Tiotropium/Olodaterol

Patient-Reported Dyspnea Scores After 6 Weeks of Treatment

Annualized Rate of Moderate or Severe Exacerbations: SPARK

Clinician Perspective on Which Patients May Be Most Suited for Dual Bronchodilation

Time to Effect of Single Dose of Umeclidinium/ Vilanterol vs Monocomponents or Placebo

Patients Determine the Effect of Therapy on Symptom Control

Lung Function Improvement With Umeclidinium/Vilanterol vs Fluticasone/Salmeterol

Time to First Moderate or Severe COPD Exacerbation for Indacaterol/Glycopyrronium vs Salmeterol/Fluticasone

FLAME Study Design and Objective

Time to First Exacerbation for Indacaterol/ Glycopyrronium vs Salmeterol/Fluticasone

Rate of Exacerbation by Specific Subgroups

Most Frequent AEs: FLAME Study

Lung Function With Triple Therapy: LAMA + LABA/ICS vs LABA/ICS + Placebo

Real-Life Use of ICS

Effect of ICS Withdrawal on Lung Function and Exacerbations

ICS Withdrawal and Exacerbations in Patients With Severe COPD: WISDOM

Risk of Severe COPD Exacerbation After ICS Withdrawal

New Data and a Shift in Treatment Strategy?

Role of Bronchodilators as Basis of Treatment

Post Hoc Analysis of FORWARD Study Data According to Blood EOS

Prospective Study of Blood Eosinophil Level and Exacerbation Rate in FLAME

Concluding Remarks

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.